Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.
D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004452:Echocardiography; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D005424:Flecainide; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010880:Piperidines / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013318:Stroke Volume
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D005424:Flecainide